| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 80.7 | 70.7 | 70.7 |
| Other income | -1.0 | 2.9 | -1.8 |
| Total income | 79.7 | 73.6 | 69.0 |
| Profit before exceptional items & tax | 2.1 | 1.4 | 0.9 |
| Profit before tax | 2.1 | 1.4 | 0.9 |
| Net profit | 1.3 | 0.6 | 0.3 |
| Operating margin | 2.6% | 1.9% | 1.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +333.30% |
|---|---|
| Net profit, quarter on quarter | +116.70% |
| Revenue, year on year | +14.10% |
| Operating profit, year on year | +14.80% |
| Operating profit, quarter on quarter | +306.70% |
NSE results filing, NSE: BALAXI. Figures extracted from the filing.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹22.76
- Market cap
- ₹125.7 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 51.8×Sector 47.4×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.
Balaxi Pharmaceuticals Management Change
Balaxi Pharmaceuticals Limited shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director for a second five-year term starting September 5, 2026.
Balaxi Pharmaceuticals Annual General Meeting
Balaxi Pharmaceuticals Limited held its 83rd Annual General Meeting on August 24, 2026. Shareholders voted on financial statements and director re-appointments during the proceedings.
Balaxi Pharmaceuticals Investor Presentation: Key Takeaways
Balaxi reported 14.1% YoY revenue growth in Q1 FY27, driven by market diversification and its first proprietary manufacturing facility. Strategy emphasizes backward integration in Latin America and Africa.
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals Limited has released its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report forms part of the company's Annual Report.